Home Contact Us 中文 English
Yourlocation:Home >News> Trimebutine maleate effects clinical

Trimebutine maleate effects clinical

Time:2015/9/16 2:15:59

Since Trimebutine maleate is available in many countries,in various forms (Table 1), extensive clinical experience has accumulated, showing that it is active in many indications with

a good safety profile (Tables 2 and 4).

Trimebutine maleate is available at various dose strengths; the usual daily dose is between 300mg (3 X 100 mg) and 600 mg a day (3 X 200mg).

IRRITABLE BOWEL SYNDROME Irritable bowel syndrome (IBS) is a frequent cause of patients being referred to gastroenterologists.?' The diagnosis ofIBS is based on the clinical history when endoscopic and laboratory tests have excluded an organic disease. IBS is usually chronic and characterized by the association of abdominal pain with change in bowel habits, presence of mucus in the stools, etc. 9 5 The clinical course of patients with IBS may be characterized by periods of quiescence or by sudden attacks of abdominal pain, which may interfere with the patient's work, social and family life.

The aetiology of IBS is not clear and may differ between patients. In some it is a sequel to a severe acute gastroenteritis (traveller's diarrhoea). IBS may be exacerbated by specific constituents in the diet (caffeine,dairy products, alcohol), and by exposure to mental stress. Trimebutine maleate has been shown to be effective in IBS; the results of clinical trials have indicated the therapeutic protocols to be used in different conditions. In IBS patients, it is important to distinguish between the treatment of acute attacks of abdominal pain and maintenance therapy, which is mainly based on the use of musculotropic drugs modulating gastrointestinal motility and drugs acting on intestinal transit.